Chicken Lips
07 Oct 2016
Re: Feedback from presentation. Thanks ad look forwards to next few months to see the progress Uk and Europe.
Baffler
07 Oct 2016
Re: Feedback from presentation. Hello Chickenlips,I am sure a great part of the story is the USA but the feeling that I got is that we shouldn't make it the be all and end all.It was made clear the growth and strength of the business in Europe. It was believed that this will grow in the months ahead based on milestones being passed.Cash is ok for now but of course if the various trials prove to be very successful, then more will be needed obviously.Rock solid and heading in the right direction now that overhang has been cleared. This will respond to news in a more posiive way than it has of lateimpo/dyor
Chicken Lips
07 Oct 2016
Re: Feedback from presentation. Hi BafflerNew to this one but hold other pharma. Can you give a little more info on the forum? Like the look of the allergy opportunities, is the long term profit due to US trials?Tha
Baffler
07 Oct 2016
Feedback from presentation. I attended the Proactive forum last evening and enjoyed a very positive message and presentation from the CEO.I came away with a feeling that positive opportunities are all around us and are being managed in a sensible way.It appears that the company were really puzzled by the failure of the USA trials.The large overhang has been cleared it is believed. Will we see a holdings notice?All seems to be good for the medium/longer term shareholder.Anyone over the age of 95 may wish to consider carefully this opportunity.dyor/impo.
d gaser
06 Oct 2016
value could double in twelve months An interesting article suggesting AGY could be worth 53p in twelve months time see link below Be HappyDave www.proactiveinvestors.co.uk/companies/news/128137/allergy-therapeutics-revenues-top-forecasts-128137.html [link]
midcapper
03 Oct 2016
Director Buys Possibly the most encouraging information recently published is the £50,000 aggregate purchases of three different directors. With the s'price bumping along near its 12 month low, my hope is that there is only upside from what appears to be a "Brexit-proof" business.
Baffler
01 Oct 2016
Hardman and Co update - well worth reading, impo. [link]
Baffler
29 Sep 2016
Panmure Gordon Frome elsewhere on the webAllergy Therapeutics plc 198.6% Potential Upside Indicated by Panmure Gordon by: Amilia Stone 26th September 2016 Allergy Therapeutics plc using EPIC/TICKER code LON:AGY has had its stock rating noted as ‘Retains’ with the recommendation being set at ‘BUY’ this morning by analysts at Panmure Gordon. Allergy Therapeutics plc are listed in the Health Care sector within AIM. Panmure Gordon have set their target price at 53 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 198.6% from today’s opening price of 17.75 GBX. Over the last 30 and 90 trading days the company share price has decreased 1.35 points and decreased 1.3 points respectively. Allergy Therapeutics plc LON:AGY has a 50 day moving average of 19.03 GBX and a 200 day moving average of GBX. The 1 year high for the stock price is 34.82 GBX while the 52 week low for the stock is 17.29 GBX. There are currently 601,432,778 shares in issue with the average daily volume traded being 252,540. Market capitalisation for LON:AGY is £106,934,752 GBP. Allergy Therapeutics plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy. The Company’s business segments are Central Europe, Southern Europe, the United Kingdom and Rest of World.
nk1999
27 Sep 2016
Numis From Citywire:"Allergy Therapeutics trading at a significant discount: buy Allergy Therapeutics (AGY) is trading at a discount to peers and additional upside is in the pipeline. Numis analyst Paul Cuddon retained his ‘buy’ recommendation and target price of 37p on the shares, which fell 5.4% to 17.4p yesterday.‘Revenue growth of 19% on constant currency reflects Allergy Therapeutics’ strong performance in Europe, and in our opinion more than compensates for the setback in US development,’ he said. ‘We continue to see a strong outlook for the business in Europe and following the disappointing commercial performance of daily tables in the US, ultimately see it as the best-placed company to crack the larger US market, with a treatment format that suits the US allergists’ preference for injections. ‘The shares trade at a material discount to peers with significant additional upside from the pipeline, which now includes a promising peanut vaccine.’ "
Dino78
27 Sep 2016
TV Interviews Morning - new films for Allergy. Results film and re-edited Overview filmwww.fmp-tv.co.uk/company/allergy-therapeutics-investors-video-and-news/
Baffler
26 Sep 2016
Two words that matter most I have been traveling all day but see another fall in the price. May I ask if the 17.38 were in fact Buy trades and not a reported sell trades? Any update appreciated. AGY have certainly got some people they have upset judging by the sheer volume of shares that have materialised - a holdings notice coming? Nice one Manuel buying a hundred k The are two lots of two words that will change everything here impo. The first pair are PROGRESS /USA and the second pair are SUCCESS/USA. My money certainly looks safe tonight but the Cadillac et al will have wait until they RNS those two words. lol impo/dyor
II Editor
26 Sep 2016
NEW ARTICLE: Allergy Therapeutics tipped to bounce back " Successful investors find undervalued companies that have either been overlooked by the market or have fallen out of favour. It's a risky business, but two City brokers reckon they have found such a gem in LSE:AGY:Allergy Therapeutics. However, ..."[link]
Baffler
16 Aug 2016
Question How much hang is there in an over' hang'? Bottomless pit it seems, was somebody mighty hurt by the dosage failure?Will this warrant a holdings notice?More questions than answers I fear.
Baffler
10 Aug 2016
Just how big is this hole? Am I alone in being amazed at the constant support for AGY with over 100 buy trades in the last week or so and no movement.Whatever volume was dropped it must have been significant. Nice to see the level of confidence and with euro/pound where it is. It is no wonder! September 26th. give the company a chance to update on the USA re-trialsimpo/dyor
Baffler
22 Jul 2016
Re: IC Article Thank you. There is or has been an overhang that has been dropped into the market in 30,000 tranches. Let's hope that it has been shifted. Another 3 tranches went through today I believe.impo/dyor
